Friday, January 15, 2021
7:30 AM - 4:30 PM EST
This course is a comprehensive review of hematologic malignancies focusing on research developments over the preceding year and their application to the patient care journey. Didactic presentations will include case discussion with Penn faculty and community experts. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application.
Who Should Attend
This activity has been designed for hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer.
At the completion of this course, participants should be able to:
- Identify clinical features, including differential diagnoses for the various hematologic malignancies
- Implement strategies that incorporate state-of-the-art genomic analyses for hematologic malignancies
- Select patients with potential eligibility for immunotherapy
- List appropriate clinical trials for hematologic malignancies
- Identify the major patient management issues experienced by the interprofessional care team associated with hematologic malignancies
- Apply new strategies for incorporating therapies that target metabolism in blood cancers
- Identify the risk of infection with the novel coronavirus and severity of illness with COVID-19 in populations of patients with hematologic and solid tumor malignancies